—
The most common reasons for dose reductions were mucositis and pneumonitis1
Recommended dose reductions in response to adverse reactions | |
---|---|
Starting dose | 100 mg/m2 |
Recommended dose reductions | |
First reduction | 75 mg/m2 (25% reduction from 100 mg/m2) |
Second reduction | 56 mg/m2 (25% reduction from 75 mg/m2) |
Third reduction* | 45 mg/m2 (20% reduction from 56 mg/m2) |
*
Permanently discontinue FYARRO in patients who are unable to tolerate FYARRO after 3 dose reductions.
In the AMPECT study, stomatitis was the most common adverse reaction with FYARRO. Supportive care measures, including use of steroid mouthwash and/or other oral treatments were permitted during the study2
In the AMPECT study, stomatitis was the most common adverse reaction with FYARRO. Supportive care measures, including use of steroid mouthwash and/or other oral treatments were permitted during the study2
AMPECT=Advanced Malignant PEComa Trial.
References: 1. Wagner AJ, Ravi V, Riedel RF, et al. nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors. J Clin Oncol. 2021;39(33):3660-3670. doi:10.1200/JCO.21.01728 2. Data on file. Aadi Bioscience, Inc.; 2021.